SCHEMBL2965176

SCHEMBL2965176

CCOC(=O)COCCOCCOC

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 2/20 0.44
MGAM O43451 1/20 0.44
SI P14410 1/20 0.44
MGAM2 Q2M2H8 1/20 0.44
ALDH1A1 P00352 7/20 0.41
TRPA1 O75762 1/20 0.41
TSHR P16473 3/20 0.39
CYP3A4 P08684 3/20 0.39
ALOX15 P16050 3/20 0.39
TDP1 Q9NUW8 2/20 0.39
CYP1A2 P05177 1/20 0.36
HSD17B10 Q99714 2/20 0.36
LMNA P02545 1/20 0.36
NPSR1 Q6W5P4 1/20 0.35
ABCB11 O95342 1/20 0.35
ADRA2B P18089 1/20 0.35
OPRD1 P41143 1/20 0.35
SCN5A Q14524 1/20 0.35
SOAT1 P35610 1/20 0.34
THRB P10828 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4849311 1.00 GAA (0.44) GAAMGAMSIMGAM2ALDH1A1
SCHEMBL12967099 1.00 GAA (0.44) GAAMGAMSIMGAM2ALDH1A1
SCHEMBL5359530 1.00 GAA (0.44) GAAMGAMSIMGAM2ALDH1A1
SCHEMBL2963385 0.98 GAA (0.46) GAAMGAMSIMGAM2ALDH1A1
SCHEMBL28174051 0.93 ALDH1A1 (0.40) GAAMGAMSIMGAM2ALDH1A1
SCHEMBL28137354 0.93 ALDH1A1 (0.40) GAAMGAMSIMGAM2ALDH1A1
SCHEMBL6665142 0.91 GAA (0.52) GAAMGAMSIMGAM2ALDH1A1
SCHEMBL11163358 0.89 GAA (0.55) GAAMGAMSIMGAM2ALDH1A1
SCHEMBL29709224 0.88 ALDH1A1 (0.50) GAAALDH1A1TSHRCYP3A4TDP1
SCHEMBL25145000 0.86 TSHR (0.47) GAAMGAMSIMGAM2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7041721-B2 Highly neutralized polymer golf ball compositions including oxa acids and methods of making same ACUSHNET COMPANY (US) 2006-05-09 US claimed
EP-0910362-B1 OXA ACIDS AND RELATED COMPOUNDS FOR TREATING SKIN CONDITIONS AVON PROD INC (US) 2004-10-27 EP claimed
US-20030225197-A1 Highly neutralized polymer golf ball compositions including oxa acids and methods of making same JPMORGAN CHASE BANK, N.A., AS SUCCESSOR ADMINISTRATIVE AGENT 2003-12-04 US claimed
CN-1110302-C Oxa acids and related compounds for treating skin conditions AVON PROD INC (US) 2003-06-04 CN claimed
US-6534543-B2 Topical compositions with carboxy acid/ester, amide, or thioester/thioacid groups, with one or more of ether, amine, or sulfide groups; for example 3,6-dioxaheptanioic acid; peeling skin, softening hair AVON PRODUCTS, INC. 2003-03-18 US claimed
US-20020040056-A1 Oxa acids and related compounds for treating skin conditions AVON PRODUCTS, INC. 2002-04-04 US claimed
US-6350795-B1 ACOUSTIC PHASE-CHANGE CONDUCTIVE INK CONTAINING LOW MOLECULAR WEIGHT OXYALKYLENE SEGMENTS COMPLEXED WITH UREA DERIVATIVES XEROX CORPORATION 2002-02-26 US claimed
JP-2000511900-A 2000-09-12 JP claimed
US-6096125-A Ink compositions XEROX CORPORATION (US) 2000-08-01 US claimed
EP-0910362-A4 OXA ACIDS AND RELATED COMPOUNDS FOR TREATING SKIN CONDITIONS AVON PROD INC (US) 1999-12-22 EP claimed
CN-1221342-A Oxo acids and related compounds for the treatment of skin conditions AVON PROD INC (US) 1999-06-30 CN claimed
EP-0910362-A1 OXA ACIDS AND RELATED COMPOUNDS FOR TREATING SKIN CONDITIONS AVON PRODUCTS, INC. (US) 1999-04-28 EP claimed
US-5847003-A Oxa acids and related compounds for treating skin conditions AVON PRODUCTS, INC. (US) 1998-12-08 US claimed
US-5700316-A COMPRISED OF COLORANT AND VEHICLE OF POLY(ALKYLENE OXIDE) ALKYLATE OR DIALKYLATE OR POLYOXA-ALKANOIC ESTER OR DIESTER XEROX CORPORATION (US) 1997-12-23 US claimed
WO-1997046231-A1 OXA ACIDS AND RELATED COMPOUNDS FOR TREATING SKIN CONDITIONS AVON PRODUCTS, INC. (US) 1997-12-11 WO claimed
US-9085587-B2 Inhibitors of hepatitis C virus PRESIDIO PHARMACEUTICALS, INC. (US) 2015-07-21 US disclosed
US-9085587-B2 Inhibitors of hepatitis C virus PRESIDIO PHARMACEUTICALS, INC. (US) 2015-07-21 US disclosed
WO-1997046231-A1 OXA ACIDS AND RELATED COMPOUNDS FOR TREATING SKIN CONDITIONS AVON PRODUCTS, INC. (US) 1997-12-11 WO disclosed
US-5342970-A Hydrosoluble coumarin derivatives, their preparation and their use as an enzyme substrate or for the preparation of such substrates LABORATOIRES EUROBIO (FR) 1994-08-30 US disclosed
US-4178378-A ANTIEPILEPTIC AGENT, TRANQUILIZER, AND ANTICONVULSANT CIBA-GEIGY CORPORATION (US) 1979-12-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020040056-A1 Oxa acids and related compounds for treating skin conditions OXGR1, OXA1L, CXCR1 GAA 1367/4885MGAM 1639/4885SI 1410/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.